Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
41
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Cardlytics
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Bank Partnerships And Data-Driven Marketing Will Shape Future Markets
Key Takeaways Expansion into diverse partnerships and innovative platforms increases user engagement and positions the company for sustainable revenue growth and operational scale. Enhanced data privacy compliance and advanced analytics strengthen advertiser loyalty, create pricing power, and boost recurring, high-margin revenue streams.
View narrative
US$1.63
FV
25.5% undervalued
intrinsic discount
-10.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
1 day ago
author updated this narrative
CytomX Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
Key Takeaways Success of clinical candidates and unique tumor-targeting technology could enable regulatory progress, commercial expansion, and attract additional partnerships and licensing agreements. Increasing global cancer rates and strategic industry collaborations support diversified revenue streams, improved cash flow, and long-term growth opportunities.
View narrative
US$5.75
FV
66.8% undervalued
intrinsic discount
-31.67%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
CureVac
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
GSK Milestones And Tech Focus Will Shape Oncology Amid Risks
Key Takeaways Strategic focus on innovation and R&D in oncology and infectious diseases positions CureVac for potential high-growth opportunities and revenue enhancement. Strong intellectual property, promising GSK licensing agreements, and a solid cash position bolster competitive edge and future revenue prospects.
View narrative
US$5.35
FV
2.5% overvalued
intrinsic discount
-33.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
18 days ago
author updated this narrative
Bankwell Financial Group
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Technology Investments And SBA Expansion Will Advance Community Banking
Key Takeaways Expansion of deposit teams and digital efficiencies are strengthening growth, reducing funding costs, and improving profitability while broadening market reach. Enhanced SBA lending, better asset quality, and favorable market dynamics are diversifying income streams and supporting sustainable long-term revenue growth.
View narrative
US$45.00
FV
10.5% undervalued
intrinsic discount
28.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
Holcim
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
Aggressive Projections Will Falter Amid Regulatory And Market Risks
Key Takeaways High expectations for demand growth and margin expansion may be difficult to meet if market, regulatory, or competitive conditions shift unfavorably. Risks around regulatory costs, disruptive new materials, and integration of acquisitions could undermine profitability and long-term growth assumptions.
View narrative
CHF 65.77
FV
2.8% overvalued
intrinsic discount
-11.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
37
users have followed this narrative
2 days ago
author updated this narrative
Bloom Energy
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Fuel Cell Technology Will Transform On-Site Power Markets
Key Takeaways Growing demand for resilient, onsite power and strong policy support are boosting Bloom's market opportunity, margin outlook, and long-term revenue prospects. Product cost reductions and expansion into recurring service revenues are expected to improve profitability, cash flow stability, and earnings quality.
View narrative
US$34.57
FV
31.0% overvalued
intrinsic discount
19.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
32
users have followed this narrative
8 days ago
author updated this narrative
Claritev
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Key Takeaways Accelerated AI adoption, cloud migration, and automation initiatives enhance product development, operational efficiency, and margin stability, supporting long-term cash flow and reinvestment potential. Expansion into international and emerging markets, along with strong client renewals and strategic partnerships, underpins sustainable revenue growth and broadens Claritev's market reach.
View narrative
US$70.50
FV
1.6% overvalued
intrinsic discount
3.14%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
1 day ago
author updated this narrative
Marksans Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Developed Markets Will Support Affordable Generic Expansion
Key Takeaways Expansion in developed markets and increased production capacity are set to drive sustained revenue growth and improved margins. Strategic shift toward complex, value-added formulations and cost efficiencies will protect profitability amid generic drug price pressures.
View narrative
₹231.67
FV
22.9% undervalued
intrinsic discount
12.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
Updated
narrative
Gates Industrial
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Future Data Center Cooling And Mobility Will Unlock Global Markets
Key Takeaways Strong demand and innovation in multiple markets, including data centers and personal mobility, are powering revenue growth and margin expansion opportunities. Strategic R&D investment, geographic diversification, and improved balance sheet flexibility support long-term market share gains and enhanced profitability.
View narrative
US$29.20
FV
17.5% undervalued
intrinsic discount
4.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies